Galapagos Presents New Data on CAR T Cell Therapy in ATALANTA-1 Study
Galapagos NV has announced new Phase 2 data on its therapeutic candidate GLPG5101 during the annual meeting of the American Society of Hematology.
Presentation of Phase 2 Data
At the 67th annual meeting of the American Society of Hematology, Galapagos NV presented new Phase 2 data from the ATALANTA-1 study. This study assesses the CAR T cell therapy, GLPG5101, in patients with relapsed or refractory mantle cell lymphoma (MCL). The results indicate high rates of complete responses and minimal residual disease negativity, with durable responses. As of September 2, 2025, 26 patients had undergone leukapheresis, and 25 had received an infusion of GLPG5101, with a dropout rate of 4%.
Intention to Discontinue Cell Therapy Operations
Galapagos reiterated its intention to discontinue its cell therapy operations, as announced on October 21, 2025. The company continues to conduct its ongoing clinical studies and may consider any viable proposals for the acquisition of all or part of its cell therapy business during this cessation process.
About GLPG5101
GLPG5101 is a second-generation anti-CD19/4-1BB CAR-T candidate product, evaluated for its safety, efficacy, and the feasibility of its decentralized manufacturing in the ATALANTA-1 study. The primary objective of Phase 2 is to assess the objective response rate, while secondary objectives include the complete response rate, duration of response, and overall survival. The study is currently recruiting patients in the United States and Europe.
